Veeco Instruments Inc. (NASDAQ: VECO), Take-Two (NASDAQ: TTWO), Vanguard Natural Resources (NYSE: VNR), Deutsche Bank (NYSE: DB), AtriCure (NASDAQ: ATRC) and BankUnited (NYSE: BKU) ratings and price targets.
Take-Two (TTWO) is now covered by Macquarie. They have an “Outperform” rating on the firm.
Veeco Instruments Inc. (VECO) is now covered by Needham & Company. They have a “Hold” rating on the firm.
Vanguard Natural Resources (VNR) is now covered by Wunderlich. They have a “Buy” rating and a price target of $33.00 on the firm.
Deutsche Bank (DB) had its “Reduce” rating reiterated by Nomura (NYSE:NMR).
AtriCure (ATRC) had its price target raised by Kaufman Brothers from $14.00 to $16.00. They have a “Buy” rating on the firm.
BankUnited (BKU) was downgraded by Zacks Investment Research from an “Outperform” rating to a “Neutral” rating.
Showing posts with label AtriCure. Show all posts
Showing posts with label AtriCure. Show all posts
Wednesday, December 21, 2011
Veeco (VECO) (TTWO) (VNR) (DB) (ATRC) (BKU) Ratings, Price Targets
Veeco Instruments Inc. (NASDAQ: VECO), Take-Two (NASDAQ: TTWO), Vanguard Natural Resources (NYSE: VNR), Deutsche Bank (NYSE: DB), AtriCure (NASDAQ: ATRC) and BankUnited (NYSE: BKU) ratings and price targets.
Take-Two (TTWO) is now covered by Macquarie. They have an “Outperform” rating on the firm.
Veeco Instruments Inc. (VECO) is now covered by Needham & Company. They have a “Hold” rating on the firm.
Vanguard Natural Resources (VNR) is now covered by Wunderlich. They have a “Buy” rating and a price target of $33.00 on the firm.
Deutsche Bank (DB) had its “Reduce” rating reiterated by Nomura (NYSE:NMR).
AtriCure (ATRC) had its price target raised by Kaufman Brothers from $14.00 to $16.00. They have a “Buy” rating on the firm.
BankUnited (BKU) was downgraded by Zacks Investment Research from an “Outperform” rating to a “Neutral” rating.
Take-Two (TTWO) is now covered by Macquarie. They have an “Outperform” rating on the firm.
Veeco Instruments Inc. (VECO) is now covered by Needham & Company. They have a “Hold” rating on the firm.
Vanguard Natural Resources (VNR) is now covered by Wunderlich. They have a “Buy” rating and a price target of $33.00 on the firm.
Deutsche Bank (DB) had its “Reduce” rating reiterated by Nomura (NYSE:NMR).
AtriCure (ATRC) had its price target raised by Kaufman Brothers from $14.00 to $16.00. They have a “Buy” rating on the firm.
BankUnited (BKU) was downgraded by Zacks Investment Research from an “Outperform” rating to a “Neutral” rating.
Thursday, August 25, 2011
Newmont (NEM) (ANV) (STRA) (TSO) (ATRC) (CACI) Upgraded
Newmont Mining Co. (NYSE: NEM), Allied Nevada Gold Corp. (NYSE: ANV), Strayer Education, Inc. (NASDAQ: STRA), Tesoro Co. (NYSE: TSO), AtriCure (NASDAQ: ATRC) and CACI International Inc (NASDAQ: CACI) upgraded by analysts.
Newmont Mining Co. (NEM) was upgraded by RBC Capital from a “Positive” rating to an “Underperform” rating. They have a price target of $87.00 on the company, up from $67.00.
Allied Nevada Gold Corp. (ANV) was upgraded by RBC Capital from a “Positive” rating to an “Outperform” rating. They have a price target of $67.00 on the stock, up from $44.00.
Strayer Education, Inc. (STRA) was upgraded by Sterne Agee from a “Sell” rating to a “Neutral” rating.
Tesoro Co. (TSO) was upgraded by The Benchmark Company from a “Sell” rating to a “Buy” rating. They have a price target of $25.00 on the company.
AtriCure (ATRC) was upgraded by Morgan Keegan from a “Market Perform” rating to an “Outperform” rating. They have a price target of $13.00 on the company, down from $14.00.
CACI International Inc. (CACI) was upgraded by Jefferies (NYSE:JEF)from an “Underperform” rating to a “Hold” rating. They have a price target of $54.00 on the company, down from $56.00.
Newmont Mining Co. (NEM) was upgraded by RBC Capital from a “Positive” rating to an “Underperform” rating. They have a price target of $87.00 on the company, up from $67.00.
Allied Nevada Gold Corp. (ANV) was upgraded by RBC Capital from a “Positive” rating to an “Outperform” rating. They have a price target of $67.00 on the stock, up from $44.00.
Strayer Education, Inc. (STRA) was upgraded by Sterne Agee from a “Sell” rating to a “Neutral” rating.
Tesoro Co. (TSO) was upgraded by The Benchmark Company from a “Sell” rating to a “Buy” rating. They have a price target of $25.00 on the company.
AtriCure (ATRC) was upgraded by Morgan Keegan from a “Market Perform” rating to an “Outperform” rating. They have a price target of $13.00 on the company, down from $14.00.
CACI International Inc. (CACI) was upgraded by Jefferies (NYSE:JEF)from an “Underperform” rating to a “Hold” rating. They have a price target of $54.00 on the company, down from $56.00.
Wednesday, January 19, 2011
AtriCure's (NASDAQ:ATRC) AtriClip, OUS, Restructing Key Catalysts in 2011
AtriCure Inc. (NASDAQ:ATRC) has several catalysts which could drive the company in 2011, including AtriClip, OUS sales, and the restructuring of its sales territories.
Canaccord noted, "Following our attendance at Boston AF 2011 and meeting with management, we reiterate our BUY rating and increase our price target. We remain bullish on the AtriClip opportunity, and think it will also pull through higher sales of ATRC’s US Open Heart product line, which we also think will benefit from the company’s recent sales territory restructuring. We are also confident ATRC can grow OUS sales at a double-digit rate, augmented by upcoming product launches."
Canaccord Genuity maintains a "Buy" rating on AtriCure Inc. (ATRC), which closed Tuesday at $10.97, down $0.16, or 1.44 percent. Canaccord raised their price target on AtriCure from $10.75 to $13.50.
Canaccord noted, "Following our attendance at Boston AF 2011 and meeting with management, we reiterate our BUY rating and increase our price target. We remain bullish on the AtriClip opportunity, and think it will also pull through higher sales of ATRC’s US Open Heart product line, which we also think will benefit from the company’s recent sales territory restructuring. We are also confident ATRC can grow OUS sales at a double-digit rate, augmented by upcoming product launches."
Canaccord Genuity maintains a "Buy" rating on AtriCure Inc. (ATRC), which closed Tuesday at $10.97, down $0.16, or 1.44 percent. Canaccord raised their price target on AtriCure from $10.75 to $13.50.
Subscribe to:
Posts (Atom)